Description

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.

Faculty

• Palak Trivedi (Moderator)
• Amanda Ricciuto (Faculty)
• Marianne Samyn (Faculty)
• Christoph Schramm (Faculty)

This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.

Related episodes

• EASL Studio S5E4: PBC: the itch we need to scratch
• EASL Studio from EASL Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023
• EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patients

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.

Faculty

• Thomas Reiberger (Moderator)
• Juan Gonzalez-Abraldes (Faculty)
• Elisa Pose (Faculty)
• Jonel Trebicka (Faculty)

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Related episodes

• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
• EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis’ outdated?
• EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life.

This episode was scheduled according to the international calendar for the World Food Day (16 October)

Faculty

• Shira Zelber Sagi (Moderator)
• Riccardo Dalle Grave (Faculty)
• Giulio Marchesini (Faculty)

Related episodes

• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.

Faculty

• Zobair Younossi (Moderator)
• Laurent Castera (Faculty)
• Camilla Dalby Hansen (Faculty)
• Amalia Gastaldelli (Faculty)

This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).

This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.

Related episodes:

• EASL Studio S3E7: Bugs and the liver — the role of the gut microbiome in liver diseases
• EASL Studio S2E2: Fats or carbs, who is the real villain?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Thirty percent of the global population have too much fat in their liver. The big question is: Are they really sick when most will not end up with liver disease?
This episode discusses:

• How should they be assessed and by whom?
• What does this mean to healthcare systems?
• Are there downsides to systematic screening?

Faculty

• Aleksander Krag (Moderator)
• Alina Allen (Faculty)
• Manal El-Sayed (Faculty)
• Ian Rowe (Faculty

Related episode

• EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by an educational grant from NOVO NORDISK A/S.

Description

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research.

Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than ever.

Faculty

• Anna Saborowski (Moderator)
• Kelly Korreck (Faculty)
• Maria Panagioti (Faculty)
• Dina Tiniakos (Faculty)

Related Nature article by participant Kelly Korreck: How I managed my intense burnout

This episode is scheduled according to the international calendar for the World Mental Health Day (10 October).

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This episode discusses patient priorities in primary biliary cholangitis.

The management of abnormal liver blood tests has traditionally been the focus of many clinicians and industry work in this area. However, it is known that some patients have a significant symptom burden, particularly from itch, cognitive symptoms, and fatigue. The community now recognises that both biochemical improvement and symptom management are of equal importance and this must be reflected in clinical practice and research agenda.

Faculty

• Jessica Dyson (Moderator)
• Alexander Artyomenko (IPSEN Representative)
• Stuart Kendrick (GSK Representative)
• Robert Mitchell-Thain (PBC Foundation Representative)
• Pam Vig (Mirum Pharmaceuticals Representative)

This episode was scheduled according to the international calendar for the Primary Biliary Cholangitis Awareness Month.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by CymaBay Therapeutics, GSK, IPSEN, and Mirum Pharmaceuticals.